Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients
29 juil. 2020 09h00 HE
|
Denali Therapeutics Inc.
Dosing of DNL758 (SAR443122) has commenced in a randomized, double-blind, placebo-controlled Phase 1b trial to evaluate safety and effect on the immune system in severe COVID-19DNL758, discovered by...
Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi
09 juin 2020 16h30 HE
|
Denali Therapeutics Inc.
Denali and Sanofi pause DNL747(a) clinical activities based on the totality of DNL747 data and a superior profile of backup compound DNL788(b)Denali and Sanofi intend to accelerate DNL788 for...
Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine
27 mai 2020 16h30 HE
|
Denali Therapeutics Inc.
Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with DNL310 (ETV:IDS), the...
Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update
07 mai 2020 16h30 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the...
Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic
02 avr. 2020 16h30 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
27 févr. 2020 16h30 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
31 janv. 2020 20h41 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 9,000,000 shares of...
Denali Therapeutics Announces Pricing of Public Offering of Common Stock
28 janv. 2020 20h58 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 7,826,087 shares of its...
Denali Therapeutics Announces Proposed Offering of Common Stock
27 janv. 2020 16h10 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell shares of its common stock in an underwritten...
Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease
14 janv. 2020 09h00 HE
|
Denali Therapeutics Inc.
LRRK2 inhibitor DNL201 Phase 1b demonstrated high levels of target and pathway engagement and improvement of lysosomal biomarkers in patients with Parkinson’s disease LRRK2 inhibitor DNL151 Phase 1...